Projects

Head of Department
Ing. Lucia Račková, PhD.

International

Finished
  • Molecular logic lab-on-a-vesicle for intracellular diagnostics
    Program: Horizon 2020
    Duration: 1. 11. 2018 – 31. 10. 2023
  • Targeting Molecular Pathways of Glucolipotoxicity by a Novel Carboxymethylated Mercaptotriazinoindole Inhibitor of Aldo-Keto Reductase AKR1B1 In Diabetes, Inflammation and Age-related Neurodegeneration
    Program: Bilateral - other
    Duration: 1. 5. 2016 – 30. 4. 2019
  • The role of oxidative stress in apoptosis and dysfunction of pancreatic beta cells. The potential protective effect of novel pyridoindole antioxidants.
    Program: Bilateral - other
    Duration: 1. 4. 2009 – 30. 4. 2011

National

Current
  • In vitro biocompatibility testing of medical devices (MDs) and new generation bio-materials for MDs
    Program: SRDA
    Duration: 1. 7. 2020 – 30. 6. 2024
Finished
  • Bio-compatibility assessment of medical devices and novel medical device materials using in vitro methods based on 3D reconstructed human tissue models.
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2023
  • The use of mass spectrometry for comparative study of different rats strains glycoprofiles within metabolic disturbances intervention
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2023
  • -
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2023
  • Innovative approaches in toxicology of ageing
    Program: SRDA
    Duration: 1. 7. 2019 – 30. 6. 2023
  • Indole-1-acetic acid derivatives as aldose reductase inhibitors: structure – activity relationships
    Program: VEGA
    Duration: 1. 1. 2018 – 31. 12. 2021
  • Redox Homeostasis, Proteostasis and Inflammation as Potential Targets For Influencing Ageing and Age-Related Diseases: Modulation by the compounds of natural and synthetic origin
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • -
    Program: SRDA
    Duration: 1. 7. 2016 – 30. 6. 2020
  • -
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • Redox control of the professional phagocytes in blood and in the central nervous system: Molecular mechanisms and functional significance.
    Program: VEGA
    Duration: 1. 1. 2016 – 31. 12. 2018
  • -
    Program: VEGA
    Duration: 1. 1. 2012 – 31. 12. 2015
  • Cellular and molecular aspects of pharmacological regulation of neutrophil pro-inflammatory activity
    Program: SRDA
    Duration: 9. 9. 2008 – 30. 6. 2011
  • Developmental Origin of Metabolic Syndrome:Hypertension, Diabetes and Dyslipidemia
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Evaluation of activity parameters of potential inhibitors of aldose reductase – a contribution to therapy of chronic diabetic complications
    Program: VEGA
    Duration: 1. 1. 2007 – 1. 12. 2009
  • Molecular mechanisms of new drugs influencing oxidative stress - important ethiopathogenetic factor of numerous diseases
    Program: SRDA
    Duration: 1. 9. 2006 – 31. 10. 2009
  • Carboxymethylated pyridoindoles as inhibitors of aldose reductase with antioxidant activity: preclinical implicators for pharmacological prevention of diabetic complications
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
  • Specific antagonists myocardial production and secretion of p roinflammatory cytokines(IC), expression of mitogenic vasopressor peptides (MP), polyferation and pathological remodelation after myocardial infarction (MI) and in chroni heart failure (CHF)
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
Employees